Company Information
Our first approved product, ARCALYST® (rilonacept), an anti-inflammatory agent, has been available to patients in the U.S. since 2008. In late 2011, we launched EYLEATM (aflibercept) Injection, also known in the scientific literature as VEGF Trap-Eye. In November 2011, we, with our collaborator Sanofi, sought regulatory approval for ZALTRAP® (aflibercept) concentrate, also known as VEGF Trap, for previously-treated metastatic colorectal cancer. Additionally, we have filed a supplementary regulatory application to market ARCALYST for a second indication and intend to seek regulatory approval for EYLEA in a second indication.
We are a leader in human antibody technologies and have built a pipeline of antibody drug candidates against both novel and validated drug targets in diseases ranging from cancer to rheumatoid arthritis and hypercholesterolemia.
Our strategic antibody collaboration with Sanofi provides committed long-term funding and expertise to supplement our own. Our business is creating and commercializing new medicines for patients – at Regeneron our business is your health.